Blocking the Aryl Hydrocarbon Receptor Alleviates Myocardial Ischemia/Reperfusion Injury in Rats

Area of Science:

• Cardiology
• Cell Biology
• Pharmacology

Background:

• Myocardial ischemia reperfusion injury (IRI) exacerbates damage after restoring blood flow to ischemic heart tissue.
• Aryl hydrocarbon receptor (AhR) is implicated in kidney and intestinal IRI, but its role in cardiac IRI is less understood.

Purpose of the Study:

• To investigate the relationship between AhR and myocardial IRI.
• To determine the effects of AhR modulation on cardiac cells and in a rat model of myocardial IRI.

Main Methods:

• Established in vitro (H9c2 cells) and in vivo (rat myocardium) models of ischemia/reperfusion.
• Treated models with AhR antagonist (CH-223191) or agonist (FICZ).
• Assessed cardiomyocyte activity, lactate dehydrogenase (LDH), reactive oxygen species (ROS), and myocardial pathological damage.

Main Results:

• In vitro, neither AhR antagonist nor agonist provided protection against oxygen-glucose deprivation/reoxygenation (OGD/R).
• However, CH-223191 significantly reduced myocardial injury markers and damage in the in vivo ischemia/reperfusion model.
• AhR modulation demonstrated differential effects in vitro versus in vivo.

Conclusions:

• AhR plays a distinct role in myocardial IRI depending on the experimental model.
• Inhibition of AhR using CH-223191 alleviates myocardial IRI in vivo.
• Targeting AhR represents a potential therapeutic strategy for mitigating myocardial IRI.